Abstract
Cholangiocarcinoma (CCA) is a cancer of biliary epithelium. Late diagnosis and resistance to conventional chemotherapy are the major obstacles in CCA treatment. Increased expression of anti-apoptotic proteins are observed in CCA, which might confer chemoresistance. Thus, modulations of anti-apoptotic proteins leading to apoptotic induction is the focus of this study. Chromomycin A3 (CMA3), an anthraquinone glycoside-mithramycin A analog, was selected. CMA3 strongly binds to GC-rich regions in DNA, where specificity protein 1 (Sp1), a common transcription factor of apoptosis-related proteins, is preferentially bounded. The effects of CMA3 on anti-proliferation, cell cycle arrest and apoptosis induction in CCA cells were demonstrated by MTT assay, flow cytometry and western blot analysis. The results showed CMA3 suppressed cell proliferation in vitro in the nM range. At low doses, CMA3 inhibited cell cycle progression at S phase, while it promoted caspase-dependent apoptosis at higher doses. CMA3 induced effects of apoptosis were through the suppression of Sp1-related anti-apoptotic proteins, FADD-like IL-1β-converting enzyme-inhibitory protein, myeloid cell leukemia-1, X-linked inhibitor of apoptosis protein, cellular inhibitor of apoptosis and survivin. The anti-CCA effects of CMA3 were confirmed in the xenograft mouse model. CMA3 retarded xenograft tumor growth. Taken together, CMA3 induced apoptosis in CCA cells by diminishing the Sp1-related anti-apoptotic proteins is demonstrated. CMA3 might be useful as a chemosensitizing agent.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.